ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

casdatifan

Also written as “Casdatifan” and “AB521”.

Its studies are mostly in Carcinoma, Renal Cell · Clear-cell metastatic renal cell carcinoma, led by 3 companies.

Drug pageCasdatifan: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 2, 20259 company-led studies, 4 open or runningNext primary completion: Jan 29, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arcus Biosciencesits history only73 open or runningphase 3since Jun 2, 2025Nov 2, 2021May 2027phase 1 · NCT07751250
AstraZeneca11 open or runningphase 1since May 23, 2025May 23, 2025Jan 29, 2027phase 1 · NCT07000149
Exelixisits history only10 open or runningphase 1since Dec 19, 2023Dec 19, 2023none ahead

Also a collaborator on its studies: Summit Therapeutics, LG Chem and Otsuka.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2024Named casdatifanINNProposed as its International Nonproprietary Name in WHO's List 131 · before, AB521
  2. May 23, 2025First study: phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12First studyNCT07000149 · 9 enrolled · Australia, South Korea

Ahead

  1. Jan 29, 2027Primary completion: phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12NCT07000149

TargetBeta

EPAS1 →read by rule
“This is a single-institution, pilot study of oral casdatifan, a selective HIF-2α inhibitor, in patients with metastatic clear cell renal cell carcinoma refractory to prior IO- and VEGF-based therapies.”study text, by rule · the study

Other programs on EPAS1

ProgramCompanyFurthest phaseStudies
belzutifanruleMerckphase 324

Studies

The one study AstraZeneca leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07000149Diabetes Mellitus, Insulin-Dependent, 12 · Australia, South Korea1Active, not recruitingJan 29, 20279

How it is read

Names in the registry

  • “Casdatifan”, 6 entries
  • “casdatifan”, 2 entries
  • “AB521”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.